Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain.

ABSTRACT: Primary objectives: To evaluate the efficacy, safety, and tolerability of oral MOA-728 given daily in a population of subjects with chronic, non-malignant pain who have opioid-induced bowel dysfunction. Primary endpoints: The change from baseline in the number of spontaneous bowel movements (SBMs) per week during the double-blind treatment period.

DISEASE(S): Opioid Induced Bowel Dysfunction

PROVIDER: 2519808 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain

Project description:The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects administered MOA-728 who have chronic pain that is not due to cancer, and who have opioid-induced bowel dysfunction (OIBD).

| 2049918 | ecrin-mdr-crc

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

Project description:The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).

| 2045578 | ecrin-mdr-crc

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

Project description:The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.

| 2031936 | ecrin-mdr-crc

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study ofSubcutaneous MOA-728 for the Treatment of Opioid-Induced ConstipationEstudio multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos

Project description:Primary: To evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with nonmalignant pain who have opioid-induced constipation. Primary endpoints: Two coprimary efficacy endpoints are:1. the proportion of subjects having a RFBM within 4 hours of the first dose administration, and 2. the percentage of injections resulting in any RFBM within 4 hours during the double-blind period.

| 2525287 | ecrin-mdr-crc

An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 forTreatment of Opioid-Induced Constipation in Subjects With Nonmalignant PainEstudio abierto para evaluar la seguridad a largo plazo de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos en sujetos con dolor de origen no maligno

Project description:Primary: The primary objective of the study is to evaluate the long-term safety and tolerability of the subcutaneous formulation of MOA-728 in subjects with opioid-induced constipation who have nonmalignant pain. Primary endpoints: Safety and tolerability will be evaluated by collection of adverse events, laboratory assessments, physical examinations, vital signs measurements, electrocardiograms, Pain Intensity Scale, and the opioid withdrawal scales.

| 2525282 | ecrin-mdr-crc